🔗 Share this article

Given that the US undertakes unprecedented adjustments to its vaccine guidelines, a particular individual appears unexpectedly: Høeg, a US-based sports physician and public health researcher who initially gained attention by expressing skepticism about Covid shots in the pandemic and has concentrated on alleged fatalities after COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Program

Public health authorities were set to unveil sweeping changes to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would put the US at odds with many the global community with insufficient data for improved outcomes. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Høeg is set to speak at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth appointee to run the office this calendar year.

A New Direction at the FDA

Høeg's temporary position could signify a closer partnership between the drug and biologics branches as Høeg and Prasad consolidate power at the agency – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some childhood shot schedules in the US in order to be more like Denmark's approach, a society with nationalized medicine and a citizenry about the size of the state of Wisconsin.

In her initial statements, she has continued to focus on immunizations – traditionally the responsibility of Prasad, director of the FDA’s CBER – instead of drug regulation.

Concerns Over Expertise

Høeg has no obvious track record in drug development, regulation or administrative roles, which has been customary for previous heads of the CBER. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“It seems she lacks to have the necessary background” for running the drug-regulation department, remarked a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in managing a large organization. She lacks background in industry regulation.”

Former heads of the center would “understand regulatory frameworks and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that former directors who ran CBER have had.”

CDER has an enormous workload at the agency, Woodcock pointed out.

“The public just focuses on the novel medication approvals, but the generic program clears numerous generic drugs. There is also a biosimilars division, OTC medication office and other areas, and every single one have to be supervised,” Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial management aspect to the role, which manages in excess of 5,000 personnel. “It is a huge administrative position, if you execute it properly,” Woodcock added.

Official Statement and Disputed Programs

Regarding inquiries about Høeg’s fitness for the role and whether this selection represents increased cooperation among regulatory chiefs on immunizations, a press secretary stated that the “inquiries are based on inaccurate premises”.

“Her experience matches the functions of her position,” the spokesperson said, noting the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a controversial one-day medication authorization process that reportedly troubled her former heads. “By what process are these medications being chosen for this voucher program? Who takes the choices?” Howard questioned. “There is a lot of confidentiality going on at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards more relaxed rules of all drugs, except for shots.”

Public History on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, history, some experts said. She released a study using unverified public submissions to assess the rate of myocarditis following COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are riskier than they are.

Part of her “wish list” for the new administration included revising guidelines for novel immunizations and ending “optional” vaccines, she said after the election on a podcast. At the FDA, Høeg has reportedly proposed preventing teenage boys from obtaining COVID-19 vaccinations.

“She is an complete true believer who begins with her beliefs and tailors the evidence to retrofit the science in a highly misleading, dishonest way,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other skeptics, {like|